Essayer OR - Gratuit
Specialised Skill Development for GCCs in India
Bio Spectrum
|BioSpectrum India May 2025
India is a key hub for Life Sciences and Healthcare (LSHC) Global Capability Centers (GCCs).
With over 280,000 professionals, 40 per cent are focused on clinical research and using AI for healthcare advancements. The AI talent pool in India is projected to grow to 633,000 by 2025, emphasising the need for specialised skills and continuous learning to maintain its reputation as a top destination for LSHC GCCs.
India has solidified its position as a pivotal hub for Global Capability Centers (GCCs), especially in the Life Sciences and Healthcare (LSHC) sectors. These centres are instrumental in driving advancements in research and development, digital transformation, regulatory compliance, pharmacovigilance, clinical trial analytics, and supply chain management for global pharmaceutical and healthcare enterprises. To sustain this momentum, developing a workforce with specialised skills is essential. Currently, LSHC GCCs in India employ over 280,000 professionals. Of this talent pool, 43 per cent are engaged in core healthcare and R&D, 16 per cent specialise in IT, and 41 per cent focus on business process management.
This article delves into the initiatives undertaken for skill development, the contributions of industry leaders, emerging competencies, and the role of GCC consortiums in fortifying the talent pipeline for LSHC GCCs in India.
Escalating Demand for Specialised Skills in LSHC GCCs
As India cements its status as a preferred destination for LSHC GCCs, there is an escalating demand for professionals proficient in Regulatory Affairs & Compliance for navigating guidelines from authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organisation (CDSCO) of India for drug approvals; Clinical Research & Data Management for executing clinical trials, analysing real-world evidence, and managing extensive healthcare datasets.
Cette histoire est tirée de l'édition BioSpectrum India May 2025 de Bio Spectrum.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Bio Spectrum
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Bio Spectrum
Supporting India's Biopharma Expansion with Advanced, High-Performance Media
Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.
4 mins
December 2025
Bio Spectrum
Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging
Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.
1 min
December 2025
Listen
Translate
Change font size

